Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos.

Ovarian hyperstimulation syndrome (OHSS) is a serious and potentially life-threatening complication of ovulation induction. The syndrome almost always presents either after hCG administration in susceptible patients or during early pregnancy. Despite many years of clinical experience, the pathophysiology is poorly understood and there is no reliable test to predict patients who will subsequently develop severe OHSS. Nevertheless, excessive estradiol (E(2)) levels are commonly used as a predictor for the development of severe OHSS. The aim of this debate is to challenge this E(2) mythos by demonstrating the reported versatility in the chosen E(2) level in which patients develop OHSS; present pathophysiological evidence which paradoxically supports a preventive rather than a detrimental effect of E(2) against OHSS, followed by a possible explanation which may sort out the aforementioned chaos. Additional studies are required to elucidate the pathophysiology of OHSS which may ultimately lead to new strategies in the prediction, prevention and treatment of severe OHSS.

[1]  A. Achiron,et al.  The Role of Intravenous Immunoglobulin in the Prevention of Severe Ovarian Hyperstimulation Syndrome , 2004, Journal of Assisted Reproduction and Genetics.

[2]  B. Fisch,et al.  Soluble L-selectin levels during controlled ovarian hyperstimulation , 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[3]  Z. Ben-Rafael,et al.  Controlled Ovarian Hyperstimulation – A State of Endothelial Activation 1 , 2000, American journal of reproductive immunology.

[4]  N. Vlahos,et al.  The ovarian hyperstimulation syndrome. , 2000, Fertility and sterility.

[5]  A. Weissman,et al.  Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. , 2000, Fertility and sterility.

[6]  Z. Ben-Rafael,et al.  Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. , 1998, Human reproduction.

[7]  Z. Ben-Rafael,et al.  Ovarian Hyperstimulation Syndrome: A New Insight Into an Old Enigma , 1998, The Journal of the Society for Gynecologic Investigation: JSGI.

[8]  P. Carey,et al.  Neutrophil activation, vascular leak toxicity, and cytolysis during interleukin-2 infusion in human cancer. , 1997, Surgery.

[9]  R. Pardi,et al.  Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. , 1996, The Journal of clinical investigation.

[10]  Z. Rosenwaks,et al.  Reproductive endocrinology, surgery, and technology , 1996 .

[11]  Y. Zalel,et al.  Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[12]  P. Fishman,et al.  Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. , 1995, Human reproduction.

[13]  E. Wallach,et al.  Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. , 1992, Fertility and sterility.

[14]  V. Wiwanitkit,et al.  Ovarian hyperstimulation syndrome , 1991, The Lancet.

[15]  S. Stone,et al.  Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. , 1991, Human reproduction.

[16]  D. Serr,et al.  Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. , 1987, Fertility and sterility.